The first and only approved biologic to selectively target both IL-17A + IL-17F1-4

 

BIMZELX inhibits IL-17A + IL-17F, which can come from IL-23–dependent and 
IL-23–independent sources, both of which contribute to inflammation in psoriasis.1,5

 

The MOA of BIMZELX1,6,7 *

Bimzelx Schematic

 

Adapted from: Tanaka Y, Shaw S. Bimekizumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2024;20(2):155-168. 

 

IL-17F levels can be 30-50 times more abundant than IL-17A in psoriatic skin lesions. Clinical relevance of mechanism of action is unknown. For illustrative purposes only.8

 

Clinical relevance of mechanism of action unknown.

The first and only approved biologic to selectively target both IL-17A + IL-17F1-4

 

BIMZELX inhibits IL-17A + IL-17F, which can come from IL-23–dependent and 
IL-23–independent sources, both of which contribute to inflammation in psoriasis.1,5

 

The MOA of BIMZELX1,6,7*

Immune cells that produce
IL-17A & IL-17F

MOA Image 1

IL-17A & IL-17F homodimers and heterodimers bind to the same receptor complex.

MOA Image 2

BIMZELX binds to IL-17 A+A, F+F, and A+F The dual inhibition of BIMZELX neutralizes both IL-17A and F and provides more suppression of inflammation versus targeting IL-17A alone.*

MOA Image 3

Adapted from: Tanaka Y, Shaw S. Bimekizumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2024;20(2):155-168.
 

IL-17F levels can be 30-50 times more abundant than IL-17A in psoriatic skin lesions. Clinical relevance of mechanism of action is unknown. For illustrative purposes only.8

 

*Clinical relevance of mechanism of action unknown.

Targeting both IL-17A + IL-17F provides more inhibition
of inflammation vs targeting IL-17A alone.9 *

Watch BIMZELX in action

perspective moa

Explore rapid, complete, and maintained clearance from the very first dose1,10-13 *

View efficacy

From the very first dose as measured at Week 4; results were not immediate. 

Want more information about BIMZELX?

Get updates and contact a sales representative >

Demonstrated in in vitro studies.

IL=interleukin.

References: 1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. COSENTYX® [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 3. TALTZ® [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 4. SILIQ® [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC. 5. Cole S, et al. Front Immunol. 2020;11:585134. 6. Adams R, et al. Front Immunol. 2020;11:1894. 7. Tanaka Y, et al. Expert Rev Clin Immunol. 2024;20(2):155-168. 8. Oliveira DG, et al. Drug Des Devel Ther. 2021;15:1045-1053. 9. Glatt S, et al. Ann Rheum Dis. 2018;77(4):523-532.
10. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 11. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 12. Reich K, et al. Lancet. 2021;397(10273):487-498. 13. Warren RB, et al. N Engl J Med. 2021;385(2):130-141.

INDICATIONS

BIMZELX is indicated for the treatment of adults with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active ankylosing spondylitis, moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and moderate-to-severe hidradenitis suppurativa.

 

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common (≥1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue.

Most common (≥2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.

Most common (≥2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections.

Most common (≥2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection.

Please see the full Prescribing Information.

Most common (≥2%) adverse reactions in PsA, nr-axSpA, and AS include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Other most common (≥2%) adverse reactions specific to each indication include: urinary tract infections (PsA); cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections (nr-axSpA); injection site pain, rash, and vulvovaginal mycotic infections (AS).